Biomea Fusion Inc. (BMEA) Prices 9M Share IPO at $17/Sh

April 16, 2021 5:51 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Biomea Fusion, Inc. (NASDAQ: BMEA), a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers, today announced the pricing of its initial public offering of 9,000,000 shares of its common stock at a public offering price of $17.00 per share. All of the shares of common stock are being offered by Biomea. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Biomea, are expected to be $153.0 million. Biomea’s common stock is expected to begin trading on The Nasdaq Global Select Market on April 16, 2021, under the ticker symbol “BMEA.” The offering is expected to close on April 20, 2021, subject to satisfaction of customary closing conditions. In addition, Biomea has granted the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.

J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler & Co. are acting as joint book-running managers for the offering.

Registration statements relating to the securities has been filed with the Securities and Exchange Commission and was declared effective on April 15, 2021.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Equity Offerings, IPOs

Related Entities

JPMorgan, Jefferies & Co, IPO